Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
NCT ID: NCT00467259
Last Updated: 2011-12-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1271 participants
INTERVENTIONAL
2007-04-30
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
28 cm² Placebo patch
Placebo patch
placebo patch, changed twice a week for 52 weeks
Testosterone
Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Testosterone Transdermal System
Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testosterone Transdermal System
Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Placebo patch
placebo patch, changed twice a week for 52 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
45 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Warner Chilcott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johna Lucas, MD
Role: STUDY_DIRECTOR
Procter and Gamble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Study Facility
Birmingham, Alabama, United States
Research Facility
Birmingham, Alabama, United States
Research Facility
Mobile, Alabama, United States
Research Facility
Montgomery, Alabama, United States
Test Facility
Chandler, Arizona, United States
Study Facility
Peoria, Arizona, United States
Research Facility
Phoenix, Arizona, United States
Research Facility
Phoenix, Arizona, United States
Research Facility
Scottsdale, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Facility
Tucson, Arizona, United States
Study Facility
Tuscon, Arizona, United States
Site Facility
Jonesboro, Arkansas, United States
Site Facility
Little Rock, Arkansas, United States
Research Facility
Anaheim, California, United States
Research Site
Berkeley, California, United States
Research Facility
Palm Desert, California, United States
Research Facility
Pasadena, California, United States
Research Facility
San Diego, California, United States
Research Facility
San Ramon, California, United States
Test Facility
Santa Rosa, California, United States
Site Facility
Upland, California, United States
Research Facility
Vista, California, United States
Site Facility
Vista, California, United States
Site Facility
Westlake Village, California, United States
Test Facility
Denver, Colorado, United States
Research Facility
Longmont, Colorado, United States
Test Facility
New London, Connecticut, United States
Study Facility
Waterbury, Connecticut, United States
Research Facility
Washington D.C., District of Columbia, United States
Research Facility
Boynton Beach, Florida, United States
Site Facility
Clearwater, Florida, United States
Site Facility
Daytona Beach, Florida, United States
Research Facility
Gainesville, Florida, United States
Research Site
Jacksonville, Florida, United States
Site Facility
Jupiter, Florida, United States
Test Facility
Miami, Florida, United States
Research Facility
Pinellas Park, Florida, United States
Research Facility
Plantation, Florida, United States
Study Facility
South Miami, Florida, United States
Research Site
Tampa, Florida, United States
Test Facility
Vero Beach, Florida, United States
Research Facility
West Palm Beach, Florida, United States
Research Facility
Weston, Florida, United States
Research Facility
Alpharetta, Georgia, United States
Research Facility
Atlanta, Georgia, United States
Site Facility
Decatur, Georgia, United States
Site Facility
Douglasville, Georgia, United States
Site Facility
Roswell, Georgia, United States
Test Facility
Savannah, Georgia, United States
Study Facility
Idaho Falls, Idaho, United States
Test Facility
Champaign, Illinois, United States
Test Facility
Chicago, Illinois, United States
Test Facility
Indianapolis, Indiana, United States
Research Facility
Overland Park, Kansas, United States
Site Facility
Louisville, Kentucky, United States
Study Facility
Baltimore, Maryland, United States
Research Facility
Baltimore, Maryland, United States
Study Facility
Boston, Massachusetts, United States
Research Facility
Bingham Farm, Michigan, United States
Study Facility
Paw Paw, Michigan, United States
Test Facility
Saginaw, Michigan, United States
Research Facility
Edina, Minnesota, United States
Research Site
Jackson, Mississippi, United States
Test Facility
St Louis, Missouri, United States
Site Facility
Billings, Montana, United States
Research Site
Omaha, Nebraska, United States
Site Facility
Las Vegas, Nevada, United States
Test Facility
Reno, Nevada, United States
Test Facility
Moorestown, New Jersey, United States
Research Facility
New York, New York, United States
Test Facility
Raleigh, North Carolina, United States
Site Facility
Winston-Salem, North Carolina, United States
Study Facility
Winston-Salem, North Carolina, United States
Research Facility
Beachwood, Ohio, United States
Test Facility
Centerville, Ohio, United States
Research Facility
Cincinnati, Ohio, United States
Study Facility
Cincinnati, Ohio, United States
Research Facility
Cincinnati, Ohio, United States
Research Site
Cleveland, Ohio, United States
Site Facility
Cleveland, Ohio, United States
Test Facility
Columbus, Ohio, United States
Test Facility
Columbus, Ohio, United States
Research Facility
Dayton, Ohio, United States
Test Facility
Englewood, Ohio, United States
Test Facility
Oklahoma City, Oklahoma, United States
Test Facility
Tulsa, Oklahoma, United States
Site Facility
Eugene, Oregon, United States
Research Facility
Philadelphia, Pennsylvania, United States
Study Facility
Bristol, Tennessee, United States
Research Facility
Chattanooga, Tennessee, United States
Research Facility
Nashville, Tennessee, United States
Site Facility
Austin, Texas, United States
Research Facility
Carrolton, Texas, United States
Site Facility
Corpus Christi, Texas, United States
Research Facility
Dallas, Texas, United States
Test Facility
Farmers Branch, Texas, United States
Research Facility
Houston, Texas, United States
Research Facility
Irving, Texas, United States
Research Facility
Midland, Texas, United States
Research Facility
Richardson, Texas, United States
Site Facility
San Antonio, Texas, United States
Test Facility
San Antonio, Texas, United States
Study Facility
Salt Lake City, Utah, United States
Research Facility
West Valley City, Utah, United States
Research Facility
Newport News, Virginia, United States
Study Facility
Richmond, Virginia, United States
Test Facility
Richmond, Virginia, United States
Site Facility
Richmond, Virginia, United States
Research Facility
Virginia Beach, Virginia, United States
Research Facility
Virginia Beach, Virginia, United States
Site Facility
Seattle, Washington, United States
Research Facility
Tacoma, Washington, United States
Test Facility
Tacoma, Washington, United States
Research Site
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007004
Identifier Type: -
Identifier Source: org_study_id